PT. RICHMOND, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. today announced that Thomas P. Soloway, Senior Vice President and Chief Financial Officer, will present at the Acumen BioFin(TM) (Rodman & Renshaw) 9th Annual Healthcare Conference at the New York Palace Hotel on Monday, November 5, 2007 at 2:40 PM Eastern Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder. For more information, please visit the Company’s website at: http://www.transcept.com.
CONTACT: Michael Gill, Director of Communications of Transcept
Pharmaceuticals, Inc., +1-510-215-3575, mgill@transcept.com; or Investors
and Media, Stephanie Carrington, +1-646-536-7017,
scarrington@theruthgroup.com, or Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, both of The Ruth Group, for Transcept
Pharmaceuticals, Inc.
Web site: http://www.transcept.com/
